• Mineralys Therapeutics published Phase 2 Explore-CKD results for lorundrostat in Kidney International, meeting the trial’s primary endpoint.
• The 59-participant trial showed significant blood pressure reductions versus placebo in patients with uncontrolled hypertension and chronic kidney disease.
• Lorundrostat also significantly reduced urinary protein loss; adverse events were consistent with prior trials.
• Longer-term results from Explore-CKD participants enrolled in the Transform-HTN extension study are expected shortly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280705PRIMZONEFULLFEED9854820) on October 28, 2026, and is solely responsible for the information contained therein.